|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
AU2002311919B8
(en)
|
2001-05-11 |
2007-03-22 |
Ludwig Institute For Cancer Research Ltd |
Specific binding proteins and uses thereof
|
|
JP5355839B2
(ja)
|
2001-10-23 |
2013-11-27 |
ピーエスエムエー デベロプメント カンパニー， エル．エル．シー． |
Ｐｓｍａ抗体およびタンパク質マルチマー
|
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
DK1545613T3
(da)
|
2002-07-31 |
2011-11-14 |
Seattle Genetics Inc |
Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
|
|
EP2478912B1
(en)
|
2003-11-06 |
2016-08-31 |
Seattle Genetics, Inc. |
Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
|
|
AR059900A1
(es)
|
2006-03-17 |
2008-05-07 |
Genentech Inc |
Anticuerpos anti-tat226 e inmunoconjugados
|
|
PT2099823E
(pt)
|
2006-12-01 |
2014-12-22 |
Seattle Genetics Inc |
Agentes de ligação ao alvo variantes e suas utilizações
|
|
US9090693B2
(en)
*
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
|
CA2680854C
(en)
|
2007-03-15 |
2017-02-14 |
Ludwig Institute For Cancer Research |
Treatment method using egfr antibodies and src inhibitors and related formulations
|
|
PE20090943A1
(es)
|
2007-07-16 |
2009-08-05 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados
|
|
EP2176295B1
(en)
|
2007-07-16 |
2014-11-19 |
Genentech, Inc. |
Humanized anti-cd79b antibodies and immunoconjugates and methods of use
|
|
US9901567B2
(en)
|
2007-08-01 |
2018-02-27 |
Syntarga B.V. |
Substituted CC-1065 analogs and their conjugates
|
|
CN108424454B
(zh)
|
2007-08-14 |
2022-05-31 |
路德维格癌症研究所有限公司 |
靶向egf受体的单克隆抗体175及其衍生物和用途
|
|
WO2009086284A1
(en)
*
|
2007-12-21 |
2009-07-09 |
University Of Rochester |
Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neaural and glial tumors of the brain
|
|
EP2078492A1
(de)
*
|
2008-01-11 |
2009-07-15 |
Roche Diagnostics GmbH |
Bandkassette für ein medizinisches Handgerät und Blutzuckermesssystem
|
|
KR101607346B1
(ko)
|
2008-01-31 |
2016-03-29 |
제넨테크, 인크. |
항-ｃｄ７９ｂ 항체 및 면역접합체 및 사용 방법
|
|
EP2326350B1
(en)
|
2008-09-08 |
2013-09-04 |
Psma Development Company, L.L.C. |
Compounds for killing psma-expressing, taxane-resistant cancer cells
|
|
ES2647317T3
(es)
|
2008-11-03 |
2017-12-20 |
Syntarga B.V. |
Análogos de CC-1065 y sus conjugados
|
|
WO2010081004A1
(en)
|
2009-01-09 |
2010-07-15 |
Seattle Genetics, Inc. |
Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
|
|
WO2010096394A2
(en)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
|
JP2013505944A
(ja)
*
|
2009-09-24 |
2013-02-21 |
シアトル ジェネティックス， インコーポレイテッド |
Ｄｒ５リガンド薬物結合体
|
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
SG10201407757XA
(en)
|
2009-10-23 |
2015-01-29 |
Millennium Pharm Inc |
Anti-gcc antibody molecules and related compositions and methods
|
|
PL2542576T3
(pl)
|
2010-03-02 |
2016-10-31 |
|
Sposoby badań przesiewowych przeciwciał
|
|
PT3056203T
(pt)
|
2010-04-21 |
2018-02-15 |
Syntarga Bv |
Conjugados de análogos de cc-1065 e ligantes bifuncionais
|
|
EP3581206B8
(en)
|
2010-10-22 |
2025-02-19 |
Seagen Inc. |
Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
WO2012097333A2
(en)
|
2011-01-14 |
2012-07-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
|
MX353958B
(es)
|
2011-09-22 |
2018-02-07 |
Amgen Inc |
Proteinas de union al antigeno cd27l.
|
|
US9156915B2
(en)
|
2012-04-26 |
2015-10-13 |
Thomas Jefferson University |
Anti-GCC antibody molecules
|
|
AR091069A1
(es)
|
2012-05-18 |
2014-12-30 |
Amgen Inc |
Proteinas de union a antigeno dirigidas contra el receptor st2
|
|
CN104619350A
(zh)
*
|
2012-06-14 |
2015-05-13 |
Ambrx公司 |
结合到核受体配体多肽的抗psma抗体
|
|
ES2773710T3
(es)
|
2012-10-11 |
2020-07-14 |
Daiichi Sankyo Co Ltd |
Enlazadores para conjugados de anticuerpo - fármaco
|
|
WO2014061277A1
(ja)
|
2012-10-19 |
2014-04-24 |
第一三共株式会社 |
親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
|
|
CA2891280C
(en)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Ｂｃｍａ抗原結合蛋白質
|
|
EP2948478B1
(en)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
|
MX2015012549A
(es)
|
2013-03-15 |
2016-06-21 |
Abbvie Deutschland |
Formulaciones de conjugado anticuerpo anti-egfr-farmaco.
|
|
EP2968589A1
(en)
|
2013-03-15 |
2016-01-20 |
AbbVie Inc. |
Antibody drug conjugate (adc) purification
|
|
HUE056580T2
(hu)
|
2013-05-30 |
2022-02-28 |
Kiniksa Pharmaceuticals Ltd |
Onkosztatin-M-receptor antigénjét kötõ fehérjék
|
|
KR20160018579A
(ko)
*
|
2013-06-04 |
2016-02-17 |
싸이톰스 테라퓨틱스, 인크. |
활성화가능 항체를 접합하기 위한 조성물 및 방법
|
|
US10208125B2
(en)
|
2013-07-15 |
2019-02-19 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Anti-mucin 1 binding agents and uses thereof
|
|
WO2015017552A1
(en)
|
2013-08-01 |
2015-02-05 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to cd37 proteins
|
|
SG11201601424PA
(en)
|
2013-08-28 |
2016-03-30 |
Stemcentrx Inc |
Site-specific antibody conjugation methods and compositions
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
RU2016122041A
(ru)
|
2013-11-06 |
2017-12-11 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые анти-клаудин антитела и способы их применения
|
|
SG11201604664PA
(en)
|
2013-12-12 |
2016-07-28 |
Stemcentrx Inc |
Novel anti-dpep3 antibodies and methods of use
|
|
AU2014371934B2
(en)
|
2013-12-25 |
2020-01-23 |
Daiichi Sankyo Company, Limited |
Anti-TROP2 antibody-drug conjugate
|
|
RU2680404C2
(ru)
|
2014-01-10 |
2019-02-21 |
Синтон Байофармасьютикалс Б. В. |
Способ очистки cys-связанных конъюгатов антитело-лекарственное средство
|
|
RU2686085C2
(ru)
*
|
2014-01-10 |
2019-04-24 |
Синтон Байофармасьютикалс Б. В. |
Конъюгаты антитело-лекарственное средство (adc) с дуокармицином, применяемые для лечения рака эндометрия
|
|
CA2935433C
(en)
|
2014-01-10 |
2019-04-02 |
Synthon Biopharmaceuticals B.V. |
Duocarmycin anti-her2 antibody drug conjucates with activity against her2 expressing malignancies
|
|
IL310627B2
(en)
|
2014-01-31 |
2026-04-01 |
Daiichi Sankyo Co Ltd |
Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
|
|
CA2939941A1
(en)
|
2014-02-21 |
2015-08-27 |
Abbvie Stemcentrx Llc |
Anti-dll3 antibodies and drug conjugates for use in melanoma
|
|
US10464955B2
(en)
|
2014-02-28 |
2019-11-05 |
Hangzhou Dac Biotech Co., Ltd. |
Charged linkers and their uses for conjugation
|
|
JP5639294B1
(ja)
|
2014-03-26 |
2014-12-10 |
滝本技研工業株式会社 |
二酸化塩素ガスによる二酸化塩素発生装置
|
|
EP3130608B1
(en)
|
2014-04-10 |
2019-09-04 |
Daiichi Sankyo Co., Ltd. |
(anti-her2 antibody)-drug conjugate
|
|
KR102445502B1
(ko)
|
2014-04-10 |
2022-09-21 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
|
SG11201609372UA
(en)
|
2014-05-22 |
2016-12-29 |
Synthon Biopharmaceuticals Bv |
Site-specific conjugation of linker drugs to antibodies and resulting adcs
|
|
EP3160513B1
(en)
|
2014-06-30 |
2020-02-12 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
SG11201700365TA
(en)
*
|
2014-07-24 |
2017-02-27 |
Genentech Inc |
Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
|
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗ｍｆｉ２抗體及使用方法
|
|
HUE049175T2
(hu)
|
2014-09-23 |
2020-09-28 |
Hoffmann La Roche |
Eljárás anti-CD79b immunkonjugátumok alkalmazására
|
|
JP6864953B2
(ja)
|
2014-12-09 |
2021-04-28 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ａｘｌに対するヒトモノクローナル抗体
|
|
EP4592311A3
(en)
|
2015-02-16 |
2026-02-25 |
Lonza Ltd |
Antibodies
|
|
JP6433339B2
(ja)
*
|
2015-03-02 |
2018-12-05 |
キヤノン株式会社 |
情報処理システム、サーバ装置、制御方法およびプログラム
|
|
CN106153712B
(zh)
*
|
2015-04-16 |
2019-02-12 |
深圳华大生命科学研究院 |
一种多肽二硫键的定位方法
|
|
CA2989269C
(en)
|
2015-06-15 |
2020-09-22 |
Robert Yongxin Zhao |
Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
|
|
SMT202000614T1
(it)
|
2015-06-29 |
2021-01-05 |
Immunogen Inc |
Coniugati di anticorpi ingegnerizzati con cisteina
|
|
CN116059395A
(zh)
|
2015-06-29 |
2023-05-05 |
第一三共株式会社 |
用于选择性制造抗体-药物缀合物的方法
|
|
NZ739830A
(en)
|
2015-07-12 |
2021-12-24 |
Hangzhou Dac Biotech Co Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
EP3356415B1
(en)
|
2015-09-29 |
2024-05-01 |
Amgen Inc. |
Asgr inhibitors for reduzing cholesterol levels
|
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
|
WO2017067944A1
(en)
|
2015-10-19 |
2017-04-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from triple negative breast cancer
|
|
AU2016358854B2
(en)
|
2015-11-24 |
2023-02-02 |
Byondis B.V. |
Anti-5T4 antibodies and antibody-drug conjugates
|
|
CN109641955B
(zh)
|
2016-03-22 |
2022-07-08 |
国家医疗保健研究所 |
人源化抗claudin-1抗体及其用途
|
|
CN109311910B
(zh)
|
2016-03-24 |
2022-02-01 |
杜兰教育基金委员会 |
他克莫司偶联物、其组合物、及其用途
|
|
JP2019515677A
(ja)
|
2016-04-26 |
2019-06-13 |
アール．ピー．シェーラー テクノロジーズ エルエルシー |
抗体複合体ならびにそれを作製および使用する方法
|
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
|
SI3626273T1
(sl)
*
|
2016-05-17 |
2021-04-30 |
Abbvie Biotherapeutics Inc. |
Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo
|
|
US20180126000A1
(en)
|
2016-06-02 |
2018-05-10 |
Abbvie Inc. |
Glucocorticoid receptor agonist and immunoconjugates thereof
|
|
US11020686B2
(en)
*
|
2016-08-16 |
2021-06-01 |
Regeneron Pharmaceuticals, Inc. |
Methods for quantitating individual antibodies from a mixture
|
|
CA3080270A1
(en)
|
2016-10-25 |
2018-05-03 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Monoclonal antibodies binding to the cd160 transmembrane isoform
|
|
KR20220150408A
(ko)
|
2016-11-14 |
2022-11-10 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
|
WO2018098258A2
(en)
|
2016-11-23 |
2018-05-31 |
Immunogen, Inc. |
Selective sulfonation of benzodiazepine derivatives
|
|
US9839710B1
(en)
|
2016-12-08 |
2017-12-12 |
Takimotogiken Kogyo Co., Ltd. |
Chlorine dioxide gas generator
|
|
US11273155B2
(en)
|
2016-12-12 |
2022-03-15 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and immune checkpoint inhibitor
|
|
EP3554544A4
(en)
|
2016-12-16 |
2020-07-29 |
Bluefin Biomedicine, Inc. |
ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
|
|
JP6679762B2
(ja)
|
2017-01-17 |
2020-04-15 |
第一三共株式会社 |
抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート
|
|
WO2018146253A1
(en)
|
2017-02-10 |
2018-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
|
|
US11932650B2
(en)
|
2017-05-11 |
2024-03-19 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
TW202532104A
(zh)
|
2017-05-15 |
2025-08-16 |
日商第一三共股份有限公司 |
抗體－藥物結合物及其用途
|
|
US20210403573A1
(en)
|
2017-06-22 |
2021-12-30 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells
|
|
LT3661562T
(lt)
*
|
2017-08-04 |
2024-10-25 |
Amgen Inc. |
Cys-mab konjugavimo būdas
|
|
CA3074208C
(en)
|
2017-08-31 |
2023-10-03 |
Daiichi Sankyo Company, Limited |
Novel method for producing antibody-drug conjugate
|
|
IL324591A
(en)
|
2017-08-31 |
2026-01-01 |
Daiichi Sankyo Co Ltd |
Improved antibody-drug conjugate production methods
|
|
US11795229B2
(en)
|
2017-10-11 |
2023-10-24 |
Seattle Genetics, Inc. |
Methods of reducing side effects of anti-CD30 antibody drug conjugate therapy
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
CN107746424A
(zh)
*
|
2017-10-30 |
2018-03-02 |
上海药明生物技术有限公司 |
一种IgG4抗体的生物偶联方法
|
|
US20220226439A1
(en)
|
2017-11-01 |
2022-07-21 |
Seagen Inc. |
Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
|
|
BR112020010694A2
(pt)
|
2017-12-01 |
2020-11-10 |
Abbvie Inc. |
agonista de receptor de glicocorticoides e imunoconjugados do mesmo
|
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
|
WO2019183131A1
(en)
|
2018-03-19 |
2019-09-26 |
Bioventures, Llc |
Periostin antibodies and methods of using the same
|
|
TW202003047A
(zh)
|
2018-03-23 |
2020-01-16 |
美商西雅圖遺傳學公司 |
包括微管蛋白破壞劑之抗體藥物結合物治療實體腫瘤之用途
|
|
UA129352C2
(uk)
|
2018-05-07 |
2025-03-26 |
Генмаб А/С |
Способи лікування раку за допомогою комбінації антитіла до pd-1 і кон'югата антитіла до тканинного фактора та лікарського засобу
|
|
TW202506732A
(zh)
|
2018-05-07 |
2025-02-16 |
丹麥商珍美寶股份有限公司 |
使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
|
|
SG11202010496WA
(en)
|
2018-05-18 |
2020-12-30 |
Daiichi Sankyo Co Ltd |
Anti-muc1 antibody-drug conjugate
|
|
SG11202100653YA
(en)
|
2018-07-25 |
2021-02-25 |
Daiichi Sankyo Co Ltd |
Effective method for manufacturing antibody-drug conjugate
|
|
WO2020022475A1
(ja)
|
2018-07-27 |
2020-01-30 |
第一三共株式会社 |
抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
|
|
CA3108044A1
(en)
|
2018-07-31 |
2020-02-06 |
Daiichi Sankyo Company, Limited |
Treatment of metastatic brain tumor by administration of antibody-drug conjugate
|
|
EP3853251A1
(en)
|
2018-09-19 |
2021-07-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
|
|
EP3626265A1
(en)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human cd45rc antibodies and uses thereof
|
|
US20200102399A1
(en)
|
2018-10-01 |
2020-04-02 |
Seattle Genetics, Inc. |
Methods of Treating Peripheral T Cell Lymphoma Using Anti-CD30 Antibody Drug Conjugate Therapy
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
WO2020094609A1
(en)
|
2018-11-06 |
2020-05-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
|
EP3894543A1
(en)
|
2018-12-14 |
2021-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8cd45rc low tregs
|
|
US11478553B2
(en)
|
2019-02-15 |
2022-10-25 |
Wuxi Biologies Ireland Limited |
Process for preparing antibody-drug conjugates with improved homogeneity
|
|
US12109273B2
(en)
|
2019-02-15 |
2024-10-08 |
Wuxi Xdc Singapore Private Limited |
Process for preparing antibody-drug conjugates with improved homogeneity
|
|
EP3738614A1
(en)
*
|
2019-05-13 |
2020-11-18 |
Farmhispania S.A. |
Methods for producing homogeneous antibody drug conjugates
|
|
US11535634B2
(en)
|
2019-06-05 |
2022-12-27 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
CA3149494A1
(en)
|
2019-08-12 |
2021-02-18 |
Purinomia Biotech, Inc. |
Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
|
|
AU2020351751A1
(en)
|
2019-09-25 |
2022-04-21 |
Seagen Inc. |
Combination anti-CD30 ADC, anti-PD-1 and chemotherapeutic for treatment of hematopoietic cancers
|
|
WO2021064184A1
(en)
|
2019-10-04 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
|
TW202131954A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
|
|
TW202132343A
(zh)
|
2019-11-07 |
2021-09-01 |
丹麥商珍美寶股份有限公司 |
使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
|
|
EP4153628A1
(en)
|
2020-05-20 |
2023-03-29 |
Institut Curie |
Single domain antibodies and their use in cancer therapies
|
|
EP4171652A1
(en)
|
2020-06-29 |
2023-05-03 |
Genmab A/S |
Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
|
|
IL299803A
(en)
|
2020-07-17 |
2023-03-01 |
Daiichi Sankyo Co Ltd |
Production method for antibody-drug conjugate
|
|
EP4189071A1
(en)
|
2020-08-03 |
2023-06-07 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
|
CN112062855B
(zh)
|
2020-08-26 |
2024-08-30 |
北京天诺健成医药科技有限公司 |
一种含有衔接器的药物治疗剂的开发和应用
|
|
WO2022079270A1
(en)
|
2020-10-16 |
2022-04-21 |
Université D'aix-Marseille |
Anti-gpc4 single domain antibodies
|
|
CN112326623B
(zh)
*
|
2020-10-23 |
2024-05-14 |
中国人民解放军军事科学院军事医学研究院 |
一种双层拉曼分子标记的硅核银壳复合纳米标签、制备方法及免疫层析应用
|
|
CN114524878B
(zh)
|
2020-11-23 |
2024-08-02 |
康诺亚生物医药科技（成都）有限公司 |
一种双特异性抗体及其用途
|
|
CN114573703A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技（成都）有限公司 |
一种t细胞衔接器治疗剂的开发和应用
|
|
CN114573702A
(zh)
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技（成都）有限公司 |
一种新型肿瘤衔接器治疗药物的开发和应用
|
|
CN114685657B
(zh)
|
2020-12-31 |
2024-08-16 |
康诺亚生物医药科技（成都）有限公司 |
一种功能增强型抗体阻断剂的开发及其应用
|
|
US20240317890A1
(en)
|
2021-01-14 |
2024-09-26 |
Institut Curie |
Her2 single domain antibodies variants and cars thereof
|
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
WO2022200303A1
(en)
|
2021-03-23 |
2022-09-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of t cell-lymphomas
|
|
EP4320153A1
(en)
|
2021-04-09 |
2024-02-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
|
US20240209080A1
(en)
|
2021-04-10 |
2024-06-27 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
CA3216459A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
CA3217112A1
(en)
|
2021-04-30 |
2022-11-03 |
Wei Zhou |
Antibody-drug conjugate targeting nectin-4 and preparation method therefor and use thereof
|
|
EP4362982A1
(en)
|
2021-06-28 |
2024-05-08 |
Byondis B.V. |
Conjugates comprising phosphoantigens and their use in therapy
|
|
PL4401842T3
(pl)
|
2021-09-16 |
2025-11-24 |
Aboleris Pharma |
Domeny wiążące przeciwko ludzkiemu CD45RC i ich zastosowania
|
|
EP4426727A2
(en)
|
2021-11-03 |
2024-09-11 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
|
US20250051440A1
(en)
|
2021-12-14 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
|
IL316289A
(en)
|
2022-04-29 |
2024-12-01 |
Purinomia Biotech Inc |
Methods and compositions for treating diseases and disorders driven by eosinophils
|
|
WO2023213960A1
(en)
|
2022-05-06 |
2023-11-09 |
Genmab A/S |
Methods of treating cancer with anti-tissue factor antibody-drug conjugates
|
|
AU2023271317A1
(en)
|
2022-05-16 |
2024-11-07 |
Byondis B.V. |
Novel masked antibodies
|
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
|
JP2025526336A
(ja)
|
2022-07-22 |
2025-08-13 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｇａｒｐ
|
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
|
KR20250044409A
(ko)
*
|
2022-08-22 |
2025-03-31 |
수저우 바이오리노 바이오테크놀로지 리미티드 컴퍼니 |
부위 특이적 변형이 있는 항체를 제조하는 방법
|
|
JP2025536268A
(ja)
|
2022-10-12 |
2025-11-05 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｃｄ８１
|
|
CN120379696A
(zh)
|
2022-12-22 |
2025-07-25 |
拜奥迪斯私人有限公司 |
包含磷酸抗原的新的接头药物、新的缀合物及其在治疗中的用途
|
|
JP2026506554A
(ja)
|
2023-02-06 |
2026-02-25 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
多重塩基編集による遺伝子改変造血幹細胞の濃縮
|
|
WO2024170543A1
(en)
|
2023-02-14 |
2024-08-22 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cd44 antibodies and uses thereof
|
|
AU2024237541A1
(en)
|
2023-03-13 |
2025-08-28 |
Heidelberg Pharma Research Gmbh |
Subcutaneously administered antibody-drug conjugates for use in cancer treatment
|
|
CN121311250A
(zh)
|
2023-03-22 |
2026-01-09 |
信立泰生物医药公司 |
抗5t4抗原结合结构域、抗体-药物缀合物及其使用方法
|
|
EP4724110A1
(en)
*
|
2023-06-07 |
2026-04-15 |
Wuxi Xdc Singapore Private Limited |
Process for preparing antibody-drug conjugates with improved homogeneity
|
|
EP4737483A1
(en)
|
2023-06-30 |
2026-05-06 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate production method including purification step using activated carbon material
|
|
CN121311252A
(zh)
*
|
2023-07-10 |
2026-01-09 |
上海药明合联生物技术有限公司 |
抗体药物偶联物及其生产
|
|
WO2025120015A1
(en)
|
2023-12-06 |
2025-06-12 |
Institut National de la Santé et de la Recherche Médicale |
Cd5 targeting antibodies with depleting and t or b-cell activation effects
|
|
EP4624494A1
(en)
|
2024-03-29 |
2025-10-01 |
Institut Curie |
Her2 single domain antibody and uses thereof
|
|
WO2025238052A1
(en)
|
2024-05-15 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Depletion of plasmacytoid dendritic cells for the treatment of respiratory viral infections
|
|
US20260048137A1
(en)
|
2024-08-16 |
2026-02-19 |
Ardeagen Corporation |
Anti-mesothelin antibody conjugates and methods of use thereof
|
|
WO2026077659A1
(en)
|
2024-09-17 |
2026-04-16 |
Institut National de la Santé et de la Recherche Médicale |
Enrichment of genetically modified hematopoietic stem cells through epigenome editing
|
|
WO2026061986A1
(en)
|
2024-09-17 |
2026-03-26 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotide (aso)-mediated down-regulation of cd33 to safely enrich for genetically modified cells
|